Tag: DCGI
India’s medical devices industry set to grow fivefold by 2030, says...
DCGI was speaking at the conference on the classification of health products “Health Horizons: Defining the Future of Health Products” organized by PHD Chamber of Commerce and Industry in New Delhi
MedTech Mitra: A strategic initiative to empower innovators
Pursuing the vision of Viksit Bharat, India is taking a holistic approach to health with a vision to transform the health landscape in the country by 2047, says Dr Mansukh Mandaviya
Veeda engages with life sciences startups for Phase 1 trial solutions
The registered participants at the Phase 1 symposium featured life sciences start-up companies from healthcare, biopharma, industrial biotech, agriculture, and med-tech fields.
BioVoice eMagazine June 2023 | Issue 6 | Volume 4
This edition tracks the latest scenario in Indian CRO industry and analyzes whether India can become a hotspot for clinical trials. Key highlights include Expert Insights by Dr Cyrus Karkaria, President- Biotechnology, Lupin and Zoya Brar, Founder, CORE Diagnostics.
DCGI grants approval to indigenous tissue engineering scaffold for healing skin...
The researchers at Sree Chitra Tirunal Institute for Medical Science and Technology developed an innovative technology for preparing tissue engineering scaffolds from mammalian organs
Eli Lilly forays into dermatological space, launches psoriasis drug Copellor in...
Post approval from the Drugs Controller General of India, the drug will be available for treatment of adults with moderate-to-severe plaque psoriasis
Bharat Biotech’s Covaxin gets emergency approval for 6-12 age group
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study in children 2-18 years of age
Glenmark Specialty gets DCGI nod for Phase 1 clinical trial of...
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
World TB Day: TB Alliance expresses commitment to accessibility of TB...
The DCGI (Drug Controller General of India) approved TB drug, pretomanid, for conditional access under the National Tuberculosis Elimination Program (NTEP), can play a significant role towards elimination of highly drug-resistant TB in India
Biological E’s COVID-19 vaccine gets EUA nod for 12-18 years age...
The Drugs Controller General of India (DCGI) has already approved CORBEVAX for restricted use in emergency situation among adults on December 28, 2021